Back to search results

Exhaled Breath Analysis for Respiratory Diseases in ICU Patients

This study is looking at a new way to quickly diagnose lung diseases and infections in critically ill patients who are on a ventilator (breathing machine). Researchers will collect a small amount of your exhaled breath through a special tube connected to your ventilator. This will not change your medical care. They will then use advanced lab techniques called Orbitrap and MALDI mass spectrometry to analyze your breath for signs of illness. The goal is to see if this breath test can accurately detect problems like ventilator-associated pneumonia (VAP) early on. You may be able to join if you are an adult (over 18) in the ICU at OHSU, on a ventilator for non-COVID reasons, and do not have very severe breathing problems or unstable blood pressure. The study is currently unclear on its recruitment status and plans to enroll 100 participants.

Study design
This is an observational study, meaning there is no direct intervention or treatment given. It aims to enroll 100 participants.
What's involved
A small amount of your exhaled breath will be collected through a tube connected to your ventilator. This will not affect your existing medical care.
Compensation
Not stated in the trial record.
Follow-up
Your breath will be analyzed from admission to discharge, for up to 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06775106

Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

Recruiting
Not specifiedAges 18+Observational
Oregon Health and Science University
~100 participants
Updated 2025-01-14 on ClinicalTrials.gov
What's tested:There is no intervention in this observational study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Exhaled breath-based diagnostic platform for detecting ventilator-associated pneumonia (VAP) early in critically ill, mechanically ventilated patients.
Measured over Admission to discharge (up to 30 days)

Conditions

Pulmonary Disease
Critical Illness

Explore related trials

Critical IllnessLung Disorder

Where it's being run

1 sites across 1 states
Oregon1

Who to contact

Laura H Nguyen, B.S.
[email protected]
503-418-4733
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Non-COVID-19 adult consented patients (\>18yo) on ventilatory support in the ICU at OHSU

Exclusion

Patients with "severe respiratory distress" as defined by arterial pO2 of \<60 mmHg on maximal FiO2 \& optimal ventilator settings
Patient with severe hemodynamic instability as defined by (a) receiving IV infusion of 2 or more pressors or inotropic medications (Levophed, vasopressin, phenylephrine, or epinephrine) \& (b) MAP of \<60 mmHg or SB \<80 mmHg

What this trial measures

  • Exhaled breath-based diagnostic platform for detecting ventilator-associated pneumonia (VAP) early in critically ill, mechanically ventilated patients.Admission to discharge (up to 30 days)

    This platform leverages advanced breath sampling technology and a host-response-based assay to detect specific elevated neutrophil proteases during bacterial infections like VAP. The noninvasive approach provides a safer and more efficient alternative to methods like bronchoalveolar lavage (BAL). This approach can differentiate between bacterial colonization and active infection by capturing and analyzing exhaled breath, allowing clinicians to initiate more timely and targeted therapies, thereby improving patient outcomes and reducing the misuse of antibiotics.